Headlines about testosterone and the heart can seem to contradict each other. Some emphasize reassurance from newer research; others focus on warnings. The useful answer is more specific than either headline: what was studied, in whom, and what safety questions remain?
The FDA announced class-wide testosterone labeling changes in February 2025 after reviewing the TRAVERSE trial and blood-pressure studies. This guide explains that update without treating it as a guarantee for every patient, product, or way of using testosterone.
- The FDA update included a blood-pressure warning.
- Trial evidence does not apply to every use of testosterone.
- Medical history and follow-up still shape the decision.
Two changes happened together
The FDA directed removal of boxed-warning language about increased adverse cardiovascular outcomes, informed by TRAVERSE. At the same time, it required product-specific or new warnings about increased blood pressure. It retained limitations concerning age-related hypogonadism.
Those actions address different evidence. Removing one warning does not mean every cardiovascular issue has disappeared. Adding a blood-pressure warning does not erase what the trial contributed. A balanced conversation keeps both in view.
Match the evidence to the patient
Clinical research has entry criteria, treatment conditions, and follow-up. A result in a defined study population cannot automatically be extended to people using nonmedical doses or products outside the studied setting. Nor does it establish that testosterone should be taken to prevent heart disease.
Ask the clinician how the evidence applies to your diagnosis and history. The relevant question is your potential benefit and risk under a specific care plan, not whether an internet debate has declared testosterone universally safe or dangerous.
Blood pressure belongs in the plan
Tell the prescriber about hypertension, medicines used to treat it, and recent readings if available. Ask how pressure will be followed and what change should prompt contact. If home measurements are requested, ask about equipment and technique so the readings are useful.
Do not stop a blood-pressure medicine or adjust testosterone on your own in response to an isolated reading. A pattern, symptoms, and the rest of your treatment may change the interpretation.
Some histories need particular care
The Endocrine Society recommends against starting testosterone in specified situations, including uncontrolled heart failure and myocardial infarction or stroke within the preceding six months. Other safety considerations also affect eligibility. These are reasons for an individual medical assessment.
Bring dates and discharge information for major events if you have them. A generic intake checkbox may not communicate what the clinician needs to know. Existing specialist care should be part of the discussion.
Choose follow-up, not reassurance by slogan
When comparing clinics, ask how they assess cardiovascular history and coordinate with a primary-care clinician. Find out who responds if blood pressure changes between refills. Those process details are more useful than a blanket statement that treatment is safe.
Our provider reviews describe public service information. They cannot establish your personal suitability. Read the monitoring guide for other parts of a complete review, including blood counts and symptom benefit.
Sources & reading notes
Provider pages describe advertised services, not independently verified outcomes. Prices and eligibility may change. Checked September 20, 2026.